Physician profile
James Harwell
NPI 1053345157
$1,101.48
in general payments reported to CMS, 2019-2025
13 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2021: $146 · 2022: $288 · 2023: $72.41 · 2024: $283 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $261.24 | 2019-2022 | |
| Abbvie INC. | $245.11 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $175.10 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $85.73 | 2021-2024 | |
| Pfizer INC. | $72.13 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $66.60 | 2024 | |
| Vifor Pharma, INC. | $56.31 | 2019-2022 | |
| Mylan Specialty L.P. | $42.41 | 2023-2024 | Yupelri |
| Inogen, INC. | $23.35 | 2024 | |
| Merck Sharp & Dohme LLC | $22.23 | 2025 | Zerbaxa |
| Kiniksa Pharmaceuticals International, Plc | $18.82 | 2024 | Arcalyst |
| Viatris Specialty LLC | $17.85 | 2025 | Yupelri |
| Melinta Therapeutics, LLC | $14.60 | 2024 | Rezzayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Harwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.